Monday, Corcept Therapeutics Incorporated CORT released results from the open-label portion of the pivotal Phase 3 GRACE trial of its proprietary selective…
Plus Therapeutics Inc PSTV has been selected for $3 million in funding recommendation by the Department of Defense (DoD) office of…
Leiden, The Netherlands, 19 April 2024 – Amarna Therapeutics, a privately-held biotechnology company developing transformative gene therapies in a range…
On Thursday, Cerevel Therapeutics Holdings Inc. CERE released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon in Parkinson’s disease. The…
– Dr. Gill brings extensive leadership experience in transformative biotechnology platforms and drug development – HUNTSVILLE, AL, April 17, 2024…
U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 100 points on Wednesday. The Dow…
Wednesday, Sage Therapeutics Inc SAGE announced topline results from the PRECEDENT Phase 2 study of dalzanemdor (SAGE-718) in people with mild cognitive impairment…
Tuesday, Oppenheimer upgraded Avalo Therapeutics Inc AVTX, noting that its AVTX-009 is a promising drug candidate and looks forward to a Phase 2 topline…
Neumora Therapeutics Inc NMRA shares plummeted after the FDA placed a clinical hold on the company’s Phase 1 trial of NMRA-266. NMRA-266…
Monday, Viracta Therapeutics Inc VIRX reported topline results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial from both arms of…